Stockscreener 앱 받기
1.25
5.93%
0.07
시간 외 거래:
1.24
-0.01
-0.80%
전일 마감가:
$1.18
열려 있는:
$1.18
하루 거래량:
145.36K
Relative Volume:
0.92
시가총액:
$83.04M
수익:
$391.70K
순이익/손실:
$-52.34M
주가수익비율:
-1.7857
EPS:
-0.7
순현금흐름:
$-45.92M
1주 성능:
+5.04%
1개월 성능:
+8.70%
6개월 성능:
-59.15%
1년 성능:
-64.99%
1일 변동 폭
$1.14
$1.25
1주일 범위
$1.10
$1.25
52주 변동 폭
$0.68
$4.10
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Ovid Therapeutics to Host Investor Event - GlobeNewswire
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - MarketBeat
Layoff Tracker: Sage Therapeutics Will Lay Off 33% of Employees - BioSpace
Ovid Therapeutics (STU:1OT) Cyclically Adjusted Revenue per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
Ovid Therapeutics (STU:1OT) Revenue per Share : €0.01 (TTM As of Jun. 2024) - GuruFocus.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
Marinus Pharmaceuticals' patent upheld by PTAB - Investing.com
Rhumbline Advisers Sells 12,851 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents (2024) - Legal Service India
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright - Investing.com
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? - Yahoo Finance
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID) - Defense World
1,400,191 Shares in Ovid Therapeutics Inc. (NASDAQ:OVID) Bought by Driehaus Capital Management LLC - MarketBeat
Ovid stock gets boost from promising OV329 toxicity profileB.Riley - Investing.com
Ovid reports promising safety profile for epilepsy drug OV329 - Investing.com
Ovid Therapeutics Presents Pre-Clinical Study Results - GlobeNewswire
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Lombard Odier Asset Management USA Corp Has $236,000 Stock Position in V2X, Inc. (NYSE:VVX) - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Market Resilience: Vor Biopharma Inc (VOR) Finishes Weak at 0.83, Down -7.78 - The Dwinnex
Lombard Odier Asset Management Europe Ltd Makes New Investment in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
The Attractiveness of Investing In OmniAb Inc (OABI) is Growing - Knox Daily
Oxford Biomedica Sees Robust Growth in 2024 - TipRanks
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Defense World
Victory Capital Management Inc. Has $991,000 Holdings in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
DCF Advisers LLC Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Shares Cross Below Fifty Day Moving Average of $1.06 - MarketBeat
After epilepsy setback, Ovid charges confidently ahead in CNS - Yahoo Finance
Q3 2025 EPS Estimates for ModivCare Inc. (NASDAQ:MODV) Reduced by Analyst - MarketBeat
Victory Capital Management Inc. Increases Position in OneMain Holdings, Inc. (NYSE:OMF) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Stock Passes Below 50 Day Moving Average of $1.06 - Defense World
Checking in on OmniAb Inc (OABI) after recent insiders movement - Knox Daily
Is OmniAb Inc (OABI) positioned for future growth? - SETE News
Federated Hermes Inc. Purchases 5,323 Shares of Ovintiv Inc. (NYSE:OVV) - Defense World
Box announces pricing of $400M debt offering via issuance of convertible senior notes due 2029 - MSN
Oxford Biomedica Emerges as OXB with Global Vision - TipRanks
Recent Insider Activity Could Benefit Olo Inc (OLO) - Knox Daily
ModivCare (NASDAQ:MODV) PT Lowered to $19.00 - MarketBeat
Gaining Ground: Outset Medical Inc (OM) Closes Lower at 0.52, Down -1.34 - The Dwinnex
Levi & Korsinsky Notifies Outset Medical, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – OM - ForexTV.com
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology
FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - Citizentribune
Ovid Therapeutics names new President and COO - Investing.com India
Moderna Pulls Back on R&D and Delays Timeline for Profitability. The Stock Tumbles. - MSN
Moderna slashes research spending, trims pipeline as it looks to regain footing - MSN
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):